<DOC>
	<DOCNO>NCT01174537</DOCNO>
	<brief_summary>Patients specific metastatic cancer fail prior therapeutic regime treat NDV least year disease progression . The study measure progression-free disease posit extend .</brief_summary>
	<brief_title>New Castle Disease Virus ( NDV ) Glioblastoma Multiforme ( GBM ) , Sarcoma Neuroblastoma</brief_title>
	<detailed_description>Present therapeutic regime much improve survival patient metastatic cancer . Therapeutic cancer vaccine form immunotherapy design educate immune system recognise tumor cell foreign rather self . New Castle Virus ( NDV ) long history broad system oncolytic destroy tumor cell stimulate immune system . Up 30 patient suffer recurrent , refractory Glioblastoma Multiforme , soft bone sarcoma disseminate neuroblastoma enrol trial receive daily dos NDV least 5 day week minimum year disease progression .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Evidence progressive disease category evaluate standard tumor staging . Histologically confirm diagnosis . Failure conventional anti cancer modalities.despite optimal application relevant available anti cancer modality . Age 3 75 year old . Liver function test less twice normal , renal function 20 % reduction white cell platelet count 30 % reduction . Karnofsky performance status 50 % great A write informed consent understood sign patient spouse , parent guardian . In patient GBM two sign require due possible alteration psych understand . Not fulfil criterion Moribund patient patient life expectancy &lt; 3 month Karnofksy performance status &lt; 50 % Pregnant lactate woman Active local systemic infection require treatment Patients receive investigational agent History allergy egg ovaalbumin . Comorbidity life threaten clinical condition basic cancer</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>NDV</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Refractory</keyword>
	<keyword>Cancer</keyword>
	<keyword>Progression-free</keyword>
	<keyword>survival</keyword>
	<keyword>recurrent</keyword>
</DOC>